Stock listing
HKEX:2616 CStone Pharmaceuticals (基石藥業) 股價
Home listing (HKEX) of CStone Pharmaceuticals
Follow CStone Pharmaceuticals into a list and get an email when it puts out news.
Share price · HKEX:2616
$5.68 HKD -0.21 (-3.6%)
Close on Nov 20, 2026
- Day range
- $5.60 – $6.00 HKDNov 20, 2026
- Volume
- 13.97M sharesNov 20, 2026
- Market cap
- $9.05B HKDAt the close on Nov 20, 2026 · price × 1.59B shares outstanding
- 52-week range
- $4.01 – $10.41 HKDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $52.79M HKDMedian day 7.85M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| HKEX:2616 · Home | $5.68 HKD | -0.215 (-3.6%) | 13,966,500 | $6.00 | $6.00 | $5.595 | $5.895 | Close on Nov 20, 2026 |
| OTC:CSPHF | $0.75 USD | +0.061 (+8.8%) | 201 | $0.75 | $0.75 | $0.75 | $0.689 | Close on Nov 17, 2026 |
| Frankfurt:PH4 | €0.638 EUR | -0.025 (-3.8%) | — | €0.639 | €0.639 | €0.638 | €0.663 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · HKEX:2616 · HKD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $5.68 | -0.215 | -3.6% | $6.00 | $6.00 | $5.595 | 13,966,500 | |
| $5.895 | +0.435 | +8.0% | $5.46 | $6.095 | $5.315 | 16,050,954 | |
| $5.46 | +0.305 | +5.9% | $5.155 | $5.49 | $5.04 | 5,428,075 | |
| $5.155 | -0.05 | -1.0% | $5.11 | $5.23 | $5.01 | 5,260,500 | |
| $5.205 | -0.26 | -4.8% | $5.425 | $5.47 | $5.18 | 3,988,000 | |
| $5.465 | -0.015 | -0.3% | $5.48 | $5.53 | $5.32 | 4,630,000 | |
| $5.48 | 0.00 | 0.0% | $5.475 | $5.54 | $5.37 | 3,334,000 | |
| $5.48 | +0.07 | +1.3% | $5.41 | $5.575 | $5.35 | 5,141,500 | |
| $5.41 | +0.065 | +1.2% | $5.30 | $5.61 | $5.30 | 4,312,740 | |
| $5.345 | -0.29 | -5.1% | $5.20 | $5.625 | $5.20 | 6,723,479 | |
| $5.635 | +0.225 | +4.2% | $5.53 | $5.75 | $5.435 | 12,197,500 | |
| $5.41 | +0.565 | +11.7% | $4.83 | $5.41 | $4.825 | 9,091,382 | |
| $4.845 | -0.105 | -2.1% | $4.87 | $4.96 | $4.675 | 9,155,521 | |
| $4.95 | +0.01 | +0.2% | $5.00 | $5.105 | $4.79 | 5,949,000 | |
| $4.94 | +0.205 | +4.3% | $4.69 | $5.165 | $4.605 | 9,052,164 | |
| $4.735 | -0.02 | -0.4% | $4.755 | $4.88 | $4.71 | 3,955,642 | |
| $4.755 | +0.185 | +4.0% | $4.615 | $4.875 | $4.615 | 5,297,612 | |
| $4.57 | -0.355 | -7.2% | $4.99 | $4.99 | $4.53 | 7,890,500 | |
| $4.925 | +0.055 | +1.1% | $5.015 | $5.215 | $4.80 | 8,386,448 | |
| $4.87 | +0.17 | +3.6% | $4.75 | $4.875 | $4.575 | 5,146,588 | |
| $4.70 | -0.34 | -6.7% | $5.03 | $5.095 | $4.625 | 8,727,000 | |
| $5.04 | -0.045 | -0.9% | $5.13 | $5.27 | $5.025 | 3,213,000 | |
| $5.085 | +0.115 | +2.3% | $5.105 | $5.115 | $4.885 | 3,086,408 | |
| $4.97 | +0.275 | +5.9% | $4.695 | $5.06 | $4.695 | 6,431,998 | |
| $4.695 | -0.085 | -1.8% | $4.80 | $4.815 | $4.635 | 7,495,000 | |
| $4.78 | -0.20 | -4.0% | $4.98 | $4.995 | $4.775 | 8,276,000 | |
| $4.98 | -0.02 | -0.4% | $4.99 | $5.09 | $4.785 | 7,076,767 | |
| $5.00 | -0.09 | -1.8% | $5.14 | $5.295 | $5.00 | 7,109,756 | |
| $5.09 | -0.15 | -2.9% | $5.26 | $5.29 | $4.94 | 9,959,270 | |
| $5.24 | -0.545 | -9.4% | $5.745 | $5.79 | $5.23 | 10,841,500 | |
| $5.785 | -0.065 | -1.1% | $5.845 | $5.845 | $5.56 | 1,400,500 | |
| $5.85 | +0.18 | +3.2% | $5.67 | $5.915 | $5.67 | 2,786,269 | |
| $5.67 | +0.015 | +0.3% | $5.66 | $5.73 | $5.585 | 1,231,500 | |
| $5.655 | -0.245 | -4.2% | $5.895 | $5.895 | $5.42 | 4,100,584 | |
| $5.90 | +0.34 | +6.1% | $5.56 | $5.95 | $5.545 | 7,938,130 | |
| $5.56 | +0.42 | +8.2% | $5.15 | $5.64 | $5.12 | 9,457,000 | |
| $5.14 | -0.195 | -3.7% | $5.475 | $5.475 | $5.04 | 7,553,000 | |
| $5.335 | -0.04 | -0.7% | $5.39 | $5.555 | $5.25 | 1,732,500 | |
| $5.375 | -0.405 | -7.0% | $5.77 | $5.77 | $5.37 | 7,806,000 | |
| $5.78 | +0.09 | +1.6% | $5.75 | $5.875 | $5.695 | 5,608,848 | |
| $5.69 | +0.04 | +0.7% | $5.63 | $5.72 | $5.51 | 5,282,000 | |
| $5.65 | +0.315 | +5.9% | $5.38 | $5.82 | $5.38 | 11,699,374 | |
| $5.335 | -0.045 | -0.8% | $5.39 | $5.60 | $5.215 | 15,649,300 | |
| $5.38 | +0.185 | +3.6% | $5.195 | $5.44 | $5.06 | 16,464,129 | |
| $5.195 | -0.75 | -12.6% | $5.95 | $5.95 | $5.125 | 20,548,381 | |
| $5.945 | -0.03 | -0.5% | $6.02 | $6.145 | $5.825 | 25,034,500 | |
| $5.975 | +0.19 | +3.3% | $5.785 | $6.10 | $5.58 | 13,259,000 | |
| $5.785 | -0.295 | -4.9% | $5.99 | $5.99 | $5.555 | 25,003,500 | |
| $6.08 | -0.085 | -1.4% | $6.165 | $6.36 | $5.97 | 22,335,500 | |
| $6.165 | -0.01 | -0.2% | $6.24 | $6.295 | $6.00 | 24,703,000 | |
| $6.175 | +0.105 | +1.7% | $6.07 | $6.495 | $5.895 | 20,020,500 | |
| $6.07 | -0.12 | -1.9% | $6.48 | $6.58 | $5.85 | 38,957,301 | |
| $6.19 | +0.01 | +0.2% | $6.20 | $6.495 | $6.19 | 8,773,345 | |
| $6.18 | 0.00 | 0.0% | $6.28 | $6.35 | $6.015 | 5,589,302 | |
| $6.18 | +0.475 | +8.3% | $5.755 | $6.25 | $5.735 | 9,929,500 | |
| $5.705 | -0.045 | -0.8% | $5.75 | $5.86 | $5.60 | 5,200,000 | |
| $5.75 | -0.14 | -2.4% | $5.89 | $5.89 | $5.50 | 10,319,297 | |
| $5.89 | -0.48 | -7.5% | $6.55 | $6.65 | $5.73 | 13,034,000 | |
| $6.37 | +0.44 | +7.4% | $5.935 | $6.37 | $5.84 | 10,074,000 | |
| $5.93 | +0.09 | +1.5% | $5.945 | $6.155 | $5.845 | 8,285,000 | |
| $5.84 | +0.29 | +5.2% | $5.55 | $5.955 | $5.355 | 6,002,000 | |
| $5.55 | +0.165 | +3.1% | $5.59 | $5.75 | $5.40 | 6,801,000 | |
| $5.385 | -0.065 | -1.2% | $5.50 | $5.545 | $5.25 | 5,437,000 | |
| $5.45 | +0.33 | +6.4% | $5.30 | $5.715 | $5.22 | 9,548,500 |
- Ticker
- HKEX:2616
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- HKEX
- Currency
- HKD
What changed lately
Latest news release · Nov 20, 2026
Grant of share options and restricted share units
Latest deck · Aug 28, 2026
H1 2026 Earnings Presentation
Earnings · 61 slides
Latest news
Monthly return of equity issuer on movements in securities for the month ended 31 October 2026
Nov 5, 2026
Closed $5.35 (-5.1%) on Nov 6, 2026
Voluntary announcement - cstone and kimia therapeutics enter clinical development collaboration to advance a novel drug candidate targeting repair pathways critical for solid tumor survival
Nov 4, 2026
Closed $5.41 (+11.7%) on Nov 4, 2026
Voluntary announcement - cstone announces major clinical validation milestone for CS2009 at ESMO 2026: data from more than 300 patients support mechanism, safety and broad antitumor activity
Oct 25, 2026
Closed $4.93 (+1.1%) on Oct 26, 2026
Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
Oct 7, 2026
Closed $5.24 (-9.4%) on Oct 8, 2026
Interim report 2026
Sep 28, 2026
Closed $5.56 (+8.2%) on Sep 29, 2026
Voluntary announcement - increase in shareholding by CEO and executive director dr. jianxin yang by 496,000 shares, with accumulated purchase totaling 14,210,500 shares
Sep 24, 2026
Closed $5.34 (-0.7%) on Sep 25, 2026
CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
Aug 27, 2026
Closed $5.89 (-7.5%) on Aug 28, 2026
CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand
Jun 25, 2026
Closed $4.41 (-4.1%) on Jun 26, 2026
CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
Jun 11, 2026
Closed $4.46 (+2.8%) on Jun 11, 2026
CStone Pharmaceuticals on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 33 in all · newest Nov 20, 2026 · oldest 2024
- Decks
- 23 decks · latest Aug 28, 2026
Where CStone Pharmaceuticals is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| HKEX:2616 基石藥業 · Home listing · This page | HKEX | Hong Kong | HKD |
| gettex:PH4 | gettex | Germany | EUR |
| LS Exchange:A2PEFW | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2PEFW | Lang & Schwarz | Germany | EUR |
| OTC:CSPHF | OTC | United States | USD |
| Stuttgart:PH4 | Stuttgart | Germany | EUR |
| Dusseldorf:PH4 | Dusseldorf | Germany | EUR |
| Frankfurt:PH4 | Frankfurt | Germany | EUR |
| Munich:PH4 | Munich | Germany | EUR |
| Tradegate:PH4 | Tradegate | Germany | EUR |
Valuation
EV/sales 24.1× against a median of 36.1×: 3rd lowest of 6 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $7.64B HKD
- P/E
- Loss
- EV/sales
- 24.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 6.0×
- Gross margin
- 19.0%
- Operating margin
- −160.5%
- Net margin
- −162.1%
- Debt to equity
- 0.3×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| CStone Pharmaceuticals · HKEX:2616 | US$1.16B | US$974.6M | n/a | 24.1× | n/a | 6.0× | −162.1% | 0.3× | n/a |
| Taysha Gene Therapies, Inc. · NASDAQ:TSHA | US$1.21B | US$837.4M | n/a | 153× | n/a | 3.4× | n/a | 0.1× | 1.69 |
| Mineralys Therapeutics, Inc. · NASDAQ:MLYS | US$1.21B | US$585.1M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.39 |
| GH Research PLC · NASDAQ:GHRS | US$1.20B | US$841.0M | n/a | n/a | n/a | 3.4× | n/a | 0.0× | 1.28 |
| Vor Biopharma Inc. · NASDAQ:VOR | US$1.18B | US$697.4M | 0.9× | n/a | n/a | n/a | n/a | n/a | 1.25 |
| Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A · SZSE:300204 | US$1.17B | US$1.01B | n/a | 36.1× | n/a | 3.9× | −53.3% | 0.0× | n/a |
| OPKO Health, Inc. · NASDAQ:OPK | US$1.17B | US$1.26B | n/a | 2.5× | n/a | 1.0× | −29.5% | 0.4× | 0.90 |
| D&D Pharmatech Co., Ltd. · KRX:347850 | US$1.15B | US$1.12B | n/a | 549× | n/a | 11.5× | −785.5% | 0.8× | n/a |
| Structure Therapeutics, Inc. · NASDAQ:GPCR | US$1.15B | −US$82.92M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.38 |
| COMPASS Pathways Plc · NASDAQ:CMPS | US$1.14B | US$747.8M | n/a | n/a | n/a | 8.0× | n/a | 0.4× | 1.65 |
| Ascentage Pharma Group International · HKEX:6855 | US$1.11B | US$1.14B | n/a | 13.6× | n/a | 13.3× | −216.5% | 3.8× | n/a |
| Median of the others | US$1.17B | US$839.2M | 0.9× | 36.1× | 3.4× | −134.9% | 0.1× | 1.38 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 15.60 HKD · Analysts' mean
- EPS, year to Dec 2026
- -0.29 · 1 analyst
- Revenue, year to Dec 2026
- 423.2M · 2 analysts
Team and board
| Officer | Role |
|---|---|
| Jason Yang | Chief Executive Officer, President of R&D |
| Weicong Ni | Chief Financial Officer and Company Secretary |
| Yinghua Zhang | Chief Operating Officer |
| Michael Choi | Chief Business and Strategy Officer |
| Qingmei Shi | Chief Medical Officer |
| Qinzhou Qi | Head of R&D Management and Chief of Staff to the CEO |
| Yujuan La | Head of Product Development |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Aug 14, 2025 · Before open | +0.4% |
| Quarter to Mar 31, 2025 | Apr 28, 2025 | +0.3% |
| Q4 2024 | Mar 27, 2025 | −1.5% |
| Q4 2022 | Mar 15, 2023 · Before open | +7.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H1 2026 Earnings Presentation | Earnings | 61 slides | Aug 28, 2026 |
| FY2025 Earnings Presentation | Earnings | 43 slides | Mar 27, 2026 |
| H1 2025 Earnings Presentation | Earnings | 41 slides | Aug 15, 2025 |
| FY2024 Earnings Presentation | Earnings | 65 slides | Mar 28, 2025 |
| Investor Presentation (November 2024) | Investor deck | 44 slides | November 2024 |
| H1 2024 Earnings Presentation | Earnings | 40 slides | Aug 26, 2024 |
| FY2023 Earnings Presentation | Earnings | 38 slides | Mar 28, 2024 |
| FY2023 Earnings Presentation | Earnings | 38 slides | Mar 28, 2024 |
| Corporate Update (December 2023) | Corporate update | 34 slides | Dec 20, 2023 |
| H1 2023 Earnings Presentation | Earnings | 26 slides | Aug 16, 2023 |
All 23 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| FY2022 Earnings Presentation | Earnings | 33 slides | Mar 16, 2023 |
| FY2021 Earnings Presentation | Earnings | 34 slides | Jun 1, 2022 |
| Investor Presentation (May 2022) | Investor deck | 35 slides | May 2022 |
| Investor Presentation (April 2022) | Investor deck | 35 slides | April 2022 |
| Investor Presentation (February 2022) | Investor deck | 35 slides | February 2022 |
| Investor Presentation (January 2022) | Investor deck | 35 slides | January 2022 |
| Investor Presentation (November 2021) | Investor deck | 34 slides | November 2021 |
| H1 2021 Earnings Presentation | Earnings | 31 slides | Aug 27, 2021 |
| Investor Presentation (June 2021) | Investor deck | 33 slides | June 2021 |
| Investor Presentation (June 2021) | Investor deck | 34 slides | June 2021 |
| Investor Presentation (March 2021) | Investor deck | 32 slides | March 2021 |
| Investor Presentation (September 2020) | Investor deck | 36 slides | September 2020 |
| Investor Presentation (April 2020) | Investor deck | 37 slides | April 2020 |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 269.6M | 407.2M | 463.8M | 481.4M | 243.7M | 1.04B | 0 | 12.6M | 10.3M | 0 |
| Cost of revenue | 218.3M | 167.1M | 159.5M | 203.0M | 106.8M | 241.4M | 0 | 0 | 0 | |
| Gross profit | 51.2M | 240.2M | 304.3M | 278.4M | 136.9M | 797.4M | 12.6M | 10.3M | 0 | |
| Research and development | 311.5M | 134.7M | 527.8M | 614.2M | 1.30B | 1.40B | 1.40B | 850.2M | 213.4M | 247.1M |
| Selling, general and administrative | 87.3M | 33.2M | 48.7M | 63.2M | 109.2M | 86.7M | 338.6M | 191.0M | 39.3M | 15.1M |
| Operating income | -432.6M | -91.7M | -605.6M | -912.1M | -1.83B | -1.09B | -1.74B | -1.03B | -242.5M | -262.2M |
| Depreciation and amortization | 44.0M | 49.8M | 58.2M | 44.5M | 22.7M | 14.8M | 11.6M | 5.27M | 823.4K | 69.0K |
| EBITDA | -388.6M | -41.9M | -547.4M | -867.6M | -1.81B | -1.08B | -1.73B | -1.02B | -241.7M | -262.1M |
| Interest expense | 12.9M | 15.2M | 11.8M | 8.48M | 2.24M | 1.32M | 303.0K | 745.6M | 60.0K | 240.0K |
| Income before tax | -423.9M | -91.2M | -367.2M | -902.7M | -1.92B | -1.22B | -2.31B | -1.79B | -342.5M | -253.0M |
| Income tax | 13.1M | 61.9M | 67.3M | -1.10M | 748.4M | -734.0M | 0 | 0 | ||
| Net income | -437.0M | -91.2M | -367.2M | -902.7M | -1.92B | -1.22B | -2.31B | -1.75B | -308.9M | -246.1M |
| Earnings per share, basic | -0.31 | -0.07 | -0.29 | -0.77 | -1.65 | -1.04 | -2.34 | -1.77 | -0.31 | -0.25 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 754.0M | 387.9M | 996.7M | 558.7M | 742.7M | 3.02B | 1.13B | 701.3M | 83.4M | 59.5M |
| Short-term investments | 165.1M | 285.0M | 51.9M | 483.4M | 983.6M | 369.0M | 1.62B | 856.6M | 454.3M | 752.4M |
| Receivables | 33.8M | 130.9M | 172.4M | 77.1M | 117.6M | 0 | 760.0K | |||
| Inventory | 116.9M | 286.1M | 108.8M | 22.2M | 61.4M | 0 | ||||
| Current assets | 1.11B | 1.09B | 1.33B | 1.25B | 1.96B | 3.57B | 2.89B | 1.60B | 545.3M | 824.8M |
| Property, plant and equipment | 130.5M | 153.4M | 206.6M | 182.8M | 102.0M | 18.7M | 14.5M | 15.5M | 1.03M | |
| Total assets | 1.36B | 1.39B | 1.66B | 1.64B | 2.27B | 3.76B | 2.95B | 1.63B | 564.3M | 826.1M |
| Accounts payable | 77.2M | 338.0M | 246.4M | 290.4M | 414.3M | 28.0M | 37.3M | 4.56M | 302.0K | |
| Current liabilities | 510.4M | 682.0M | 850.3M | 946.5M | 932.9M | 727.0M | 458.0M | 1.11B | 113.2M | 59.2M |
| Long-term debt | 156.5M | 257.4M | 213.0M | 219.0M | 115.8M | 54.3M | ||||
| Total debt | 348.7M | 356.0M | 363.4M | 286.3M | 174.2M | 75.2M | 1.62B | |||
| Total liabilities | 741.6M | 1.03B | 1.21B | 1.19B | 1.06B | 808.3M | 469.1M | 1.12B | 113.2M | 59.2M |
| Shareholders' equity | 617.0M | 363.9M | 456.8M | 449.3M | 1.21B | 2.95B | 2.48B | 515.3M | 426.3M | 712.7M |
| Shares outstanding | 1.39B | 1.28B | 1.26B | 1.17B | 1.17B | 1.17B | 984.5M | 984.1M | 984.1M | 984.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -327.7M | -343.2M | -588.8M | -612.5M | -1.48B | -508.1M | -1.08B | -791.1M | -240.2M | -213.0M |
| Capital spending | 0 | 0 | -65.0M | -101.8M | -149.1M | -71.4M | -10.4M | -7.91M | -12.5M | -1.11M |
| Free cash flow | -327.7M | -343.2M | -653.9M | -714.3M | -1.63B | -579.5M | -1.09B | -799.0M | -252.7M | -214.1M |
| Cash from investing | 134.0M | -247.7M | 619.6M | 365.1M | -826.6M | 1.18B | -658.9M | -377.7M | 268.3M | -753.5M |
| Cash from financing | 577.8M | -12.9M | 388.4M | 28.5M | 92.3M | 1.39B | 2.09B | 1.66B | -300.0K | 1.01B |
| Share buybacks | 74.0K | 341.8M | 2.53M | 16.8M | -21.8M | 2.20B | 1.66B | 0 | 706.5M | |
| Change in cash | 365.8M | -608.7M | 438.0M | -184.0M | -2.28B | 1.90B | 425.1M | 617.9M | 23.9M | 59.5M |
Filings
Cap table
Built by 6ix from CStone Pharmaceuticals’ releases
- Common shares
- 1,594,112,329
- Fully diluted
- 1,594,112,329
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,594,112,329 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,594,112,329 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jason Yang | Chief Executive Officer, President of R&D · Since at least Aug 27, 2026 |
| Michael Choi | Chief Business and Strategy Officer · Since at least Nov 5, 2026 |
| Qingmei Shi | Chief Medical Officer · Since at least Feb 23, 2026 |
| Qinzhou Qi | Head of R&D Management and Chief of Staff to the CEO · Since at least Nov 5, 2026 |
| Weicong Ni | Chief Financial Officer and Company Secretary · Since at least Nov 5, 2026 |
| Yinghua Zhang | Chief Operating Officer · Since at least Nov 5, 2026 |
| Yujuan La | Head of Product Development · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about CStone Pharmaceuticals.